CCM
VNDA icon

Consonance Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Consonance Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,626,545
Closed -$51.1M – 35
2019
Q2 		$51.1M Sell
3,626,545
-631,813
-15% -$10.1M 3.62% 11
2019
Q1 		$78.4M Sell
4,258,358
-400,401
-9% -$9.12M 4.95% 9
2018
Q4 		$122M Buy
4,658,759
+215,000
+5% +$5.06M 8.95% 4
2018
Q3 		$102M Sell
4,443,759
-165,284
-4% -$3.37M 5.49% 5
2018
Q2 		$87.8M Buy
4,609,043
+1,536,768
+50% +$25.7M 5.66% 5
2018
Q1 		$51.8M Buy
+3,072,275
New +$51.4M 4.73% 11
2016
Q1 		– Sell
-1,093,696
Closed -$10.2M – 24
2015
Q4 		$10.2M Sell
1,093,696
-343,100
-24% -$3.42M 1.37% 12
2015
Q3 		$16.2M Buy
+1,436,796
New +$17.6M 2.28% 13
2014
Q2 		– Sell
-1,226,772
Closed -$19.9M – 27
2014
Q1 		$19.9M Buy
1,226,772
+1,122,772
+1,080% +$16M 2.97% 14
2013
Q4 		$1.29M Sell
104,000
-403,469
-80% -$4.05M 0.21% 26
2013
Q3 		$5.56M Sell
507,469
-922,329
-65% -$9.85M 1.39% 21
2013
Q2 		$11.6M Buy
+1,429,798
New +$9.63M 4.11% 12

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Consonance Capital Management's VNDA Position: Q3 2019 in Review

Consonance Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2019, closing a stake of 3,626,545 shares — an estimated $51.1M sold.

Consonance Capital Management first reported a position in VNDA in Q2 2013 and held it in 12 quarters. The position peaked at $122M in Q4 2018. 168 funds tracked by Wall St. Rank hold VNDA as of Q3 2019.

  • Consonance Capital Management reported no remaining Vanda Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Consonance Capital Management sold 3,626,545 Vanda Pharmaceuticals shares in Q3 2019, an estimated $51.1M.
  • Consonance Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • Consonance Capital Management's Vanda Pharmaceuticals position peaked at $122M in Q4 2018.
  • 168 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2019.

Based on Consonance Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.